Featured News See All January 14, 2025 REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases January 13, 2025 AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA Year All2025202420232022202120202019201820172016201520142013201220112009 Jan 14, 2025 REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases Jan 13, 2025 AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Jan 14, 2025 REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
